Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, said it submitted a new drug application to the FDA for MCI-186, edaravone, to treat amyotrophic lateral sclerosis. Mitsubishi Tanabe also said that it has established a U.S. company, MT Pharma America Inc., to commercialize products in the U.S. and is planning to expand that company's product line through various collaborations.